Spero Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
SPRO$1.01-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues: | ||
| Grant revenue | $20,581 | $7,046 |
| Collaboration revenue - related party | 27,025 | 95,802 |
| Collaboration revenue | 371 | 933 |
| Total revenues | 47,977 | 103,781 |
| Operating expenses: | ||
| Research and development | 96,757 | 51,440 |
| General and administrative | 23,704 | 25,554 |
| Restructuring | 877 | — |
| Impairment of long-term asset | — | 5,306 |
| Total operating expenses | 121,338 | 82,300 |
| Income (loss) from operations | (73,361) | 21,481 |
| Other income (expense): | ||
| Interest income | 4,735 | 3,937 |
| Other income (expense), net | 60 | (14) |
| Total other income, net | 4,795 | 3,923 |
| Net income (loss) before income taxes | (68,566) | 25,404 |
| Income tax expense | — | (2,598) |
| Net income (loss) and comprehensive income (loss) | $(68,566) | $22,806 |
| Net income (loss) per share attributable to common stockholders, basic | $(1.27) | $0.43 |
| Net income (loss) per share attributable to common stockholders, diluted | $(1.27) | $0.43 |
| Weighted average common shares outstanding, basic: | 54,037,917 | 52,703,467 |
| Weighted average common shares outstanding, diluted: | 54,037,917 | 52,989,030 |
CONSOLIDATED STATEMENTS OF
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.